519 A first-in-human, multicenter, phase 1/2, open-label study of XTX101 in patients with advanced solid tumors

• John Powderly,
• Jennifer O’Neil,
• Ekta Patel,
• Teleen Norman,
• Meghan Duncan,
• Martin Huber,
• Andrae Vandross

Affiliations

John Powderly

1Carolina BioOncology Institute, Huntersville, NC, USA

Jennifer O’Neil

Xilio Therapeutics, Waltham, MA, USA

Ekta Patel

Department of Elderly Medicine, Chelsea and Westminster Hospital, London, UK

Teleen Norman

2Xilio Therapeutics, waltham, MA, USA

Meghan Duncan

2Xilio Therapeutics, waltham, MA, USA

Martin Huber

2Xilio Therapeutics, waltham, MA, USA

Andrae Vandross

3Next Oncology, Austin, TX, USA